Oussama Darwish (@darwish_uroonc) 's Twitter Profile
Oussama Darwish

@darwish_uroonc

Associate Professor, University at Buffalo. Urologic Oncology & Robotic Surgery. Views expressed here are my own.

ID: 844544671254745088

calendar_today22-03-2017 13:41:55

241 Tweet

347 Followers

445 Following

Tom Powles (@tompowles1) 's Twitter Profile Photo

Response rates for Enfortumab vedotin + pembrolizumab = 65% (n=76) in cisplatin ineligible 1st line urothelial cancer. Gem/carbo usually has RR of 40-45% (KN361, Danube etc). Even gem/Cis struggles to get >50%. Very promising. Details on PFS & OS awaited. businesswire.com/news/home/2022…

Shahrokh F. Shariat (@drshariat) 's Twitter Profile Photo

triplet combination therapy improves survival in mHSPC compared with doublet regimens. Our findings need to be confirmed in further head-to-head trials with longer follow-up sciencedirect.com/science/articl…

Toni Choueiri, MD (@drchoueiri) 's Twitter Profile Photo

As #ESMO22 is approaching, here are my list of Top 15 #GU Oncology presentations, just based on "Titles"... This list may ultimately change after abstracts release esmo.org/meetings/esmo-… ESMO - Eur. Oncology Kate Kronig Federica Frigerio

As #ESMO22 is approaching, here are my list of Top 15 #GU Oncology presentations, just based on "Titles"...

This list may ultimately change after abstracts release 

esmo.org/meetings/esmo-…

<a href="/myESMO/">ESMO - Eur. Oncology</a> <a href="/KKronig/">Kate Kronig</a> <a href="/FedefedeFri/">Federica Frigerio</a>
Toni Choueiri, MD (@drchoueiri) 's Twitter Profile Photo

Our 30-month #KYN564 adjuvant RCC trial is published The Lancet Oncology —led by Tom Powles, presented #GU22 ASCO —Note HR 0.63 improved from 0.68, all subgroups HR<1, AND if we remove M1NED/N+/T4=> HR 0.68. Still significant/clinically relevant OncoAlert sciencedirect.com/science/articl…

Our 30-month #KYN564 adjuvant RCC trial is published <a href="/TheLancetOncol/">The Lancet Oncology</a> —led by <a href="/tompowles1/">Tom Powles</a>, presented #GU22 <a href="/ASCO/">ASCO</a> —Note HR 0.63 improved from 0.68, all subgroups  HR&lt;1, AND if we remove M1NED/N+/T4=&gt; HR 0.68. Still significant/clinically relevant <a href="/OncoAlert/">OncoAlert</a>

sciencedirect.com/science/articl…
Brian Rini, MD (@brian_rini) 's Twitter Profile Photo

Updated table of the latest data for initial IO-based therapy in IMDC Int/Poor mRCC. See thread for discussion of imperfections and thoughts.

Updated table of the latest data for initial IO-based therapy in IMDC Int/Poor mRCC. See thread for discussion of imperfections and thoughts.
Uromigos (@uromigos) 's Twitter Profile Photo

🧵#UromigosLive #ProstateCancer Poll: Emerging therapeutic approaches for the treatment of mHSPC ‼️👇POLLS TO FOLLOW‼️ (1/3) 👇

🧵#UromigosLive #ProstateCancer Poll: Emerging therapeutic approaches for the treatment of mHSPC ‼️👇POLLS TO FOLLOW‼️ (1/3) 👇
BJU International (@bjuijournal) 's Twitter Profile Photo

Oncological and safety profiles in patients undergoing simultaneous TURB and TURP Ekaterina Laukhtina Jeremy Teoh and colleagues for the EAU Young Academics Urothelial Carcinoma Working Group bjui.pub/3E5CCM5

Rashid K. Sayyid (@rksayyid) 's Twitter Profile Photo

ProtecT 15-yr PROs published overnight in NEJM Evidence: 🚩No diff in HRQoL 🚩Urine leakage (1+PPD): 24% in RP, 11% AM, 8% XRT 🚩Sexual function similar: 13% RP, 17% AM, 15% XRT 🚩Bowel function: 12% XRT vs 6% in RP/AM UroToday.com #EAU22

ProtecT 15-yr PROs published overnight in <a href="/NEJMEvidence/">NEJM Evidence</a>:
🚩No diff in HRQoL
🚩Urine leakage (1+PPD): 24% in RP, 11% AM, 8% XRT
🚩Sexual function similar: 13% RP, 17% AM, 15% XRT
🚩Bowel function: 12% XRT vs 6% in RP/AM
<a href="/urotoday/">UroToday.com</a> #EAU22
Zach Klaassen (@zklaassen_md) 's Twitter Profile Photo

#EAU23 Riccardo Campi - Refining the indication for adjuvant Pembro in ccRCC at high risk of recurrence using a risk-adapted approach UroToday.com ♦️ 82.4%: malignant tumors ♦️ 54.1%: ccRCC ♦️ 419 (28.4%): eligible for adjuvant Pembro (int-high risk: 83%; high risk: 17%) 🧵

#EAU23 <a href="/Ric_Campi/">Riccardo Campi</a> - Refining the indication for adjuvant Pembro in ccRCC at high risk of recurrence using a risk-adapted approach <a href="/urotoday/">UroToday.com</a> 

♦️ 82.4%: malignant tumors 
♦️ 54.1%: ccRCC
♦️ 419 (28.4%): eligible for adjuvant Pembro (int-high risk: 83%; high risk: 17%)

🧵
Tom Varghese Jr. MD, MS, MBA, FACS, MAMSE 🇺🇸 (@tomvarghesejr) 's Twitter Profile Photo

AmJSurgery Finally, here’s a 2021 systematic review and meta-analysis on the topic: onlinelibrary.wiley.com/doi/10.1111/ja… Take home points: - 7 RCTs - rate of surgical glove perforation in the double-gloving group was lower than that of single gloving - surgical glove perforation was lower in the

Ashish M. Kamat, MD, MBBS (@urodocash) 's Twitter Profile Photo

The IBCG Quick Guide to Non-Muscle Invasive Bladder Cancer (NMIBC) Bladder Cancer Quick Reference Sheet summarizes essential details on diagnosis, treatment options, and follow-up for NMIBC all in one convenient place #AUA24 #EAU24 #IBCG24 #ASCO24 Designed by Amanda Myers

The IBCG Quick Guide to Non-Muscle Invasive Bladder Cancer (NMIBC)

Bladder Cancer Quick Reference Sheet summarizes essential details on diagnosis, treatment options, and follow-up for NMIBC all in one convenient place  #AUA24 #EAU24 #IBCG24 #ASCO24

Designed by <a href="/AmandaMyersMD/">Amanda Myers</a>
Alumni Relations Office at AUB (@aubalumni) 's Twitter Profile Photo

This year, WAAAUB North America hosted a record number of Iftar gatherings, bringing our alumni community closer than ever! Wishing you all a joyful Eid filled with love and happiness. #EidMubarak #AUBAlumni #AUBProud